Literature DB >> 17964043

Atrial tachycardia after circumferential pulmonary vein ablation of atrial fibrillation: mechanistic insights, results of catheter ablation, and risk factors for recurrence.

Sanders Chae1, Hakan Oral, Eric Good, Sujoya Dey, Alan Wimmer, Thomas Crawford, Darryl Wells, Jean-Francois Sarrazin, Nagib Chalfoun, Michael Kuhne, Jackie Fortino, Elizabeth Huether, Tammy Lemerand, Frank Pelosi, Frank Bogun, Fred Morady, Aman Chugh.   

Abstract

OBJECTIVES: The aim of this study was to determine the mechanism of atrial tachycardia (AT) that occurs after ablation of atrial fibrillation (AF).
BACKGROUND: Patients who undergo catheter ablation of AF may develop AT during follow-up.
METHODS: Seventy-eight patients underwent an ablation procedure for AT after circumferential pulmonary vein ablation (CPVA) for AF. The 3-dimensional maps from the AF and AT procedures were compared to determine whether AT arose from a prior ablation line.
RESULTS: A total of 155 ATs were mapped, and the mechanism was re-entry in 137 (88%) and focal in 18 (12%). The most common left atrial (LA) ablation targets were the mitral isthmus, roof, and septum. The critical isthmus in 115 of the 120 LA re-entrant ATs (96%) traversed a prior ablation line, consistent with a gap-related mechanism. Catheter ablation was successful in 66 of the 78 patients (85%). After a mean follow-up of 13 +/- 10 months, 60 of the 78 patients (77%) were free of AT/AF without antiarrhythmic medications. Re-entrant septal AT was associated with recurrence (odds ratio 7.3; 95% confidence interval 1.5 to 36; p = 0.02), whereas PV isolation during the AT procedure was associated with a favorable outcome (odds ratio 0.17; 95% confidence interval 0.04 to 0.81; p = 0.03).
CONCLUSIONS: Approximately 90% of ATs after CPVA are re-entrant, and nearly all are related to gaps in prior ablation lines. These findings suggest that the prevalence of these arrhythmias may be reduced by limiting the number of linear lesions, demonstration of linear block, and pulmonary vein disconnection during the initial AF procedure.

Entities:  

Mesh:

Year:  2007        PMID: 17964043     DOI: 10.1016/j.jacc.2007.07.044

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  59 in total

1.  Pulmonary venous isolation versus additional substrate modification as treatment for paroxysmal atrial fibrillation.

Authors:  Andrew Robertson Gavin; Cameron B Singleton; John Bowyer; Andrew D McGavigan
Journal:  J Interv Card Electrophysiol       Date:  2011-09-21       Impact factor: 1.900

2.  Ethanol infusion in the vein of Marshall facilitates mitral isthmus ablation.

Authors:  José L Báez-Escudero; Percy Francisco Morales; Amish S Dave; Christine M Sasaridis; Young-Hoon Kim; Kaoru Okishige; Miguel Valderrábano
Journal:  Heart Rhythm       Date:  2012-03-07       Impact factor: 6.343

3.  2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation.

Authors:  Hugh Calkins; Gerhard Hindricks; Riccardo Cappato; Young-Hoon Kim; Eduardo B Saad; Luis Aguinaga; Joseph G Akar; Vinay Badhwar; Josep Brugada; John Camm; Peng-Sheng Chen; Shih-Ann Chen; Mina K Chung; Jens Cosedis Nielsen; Anne B Curtis; D Wyn Davies; John D Day; André d'Avila; N M S Natasja de Groot; Luigi Di Biase; Mattias Duytschaever; James R Edgerton; Kenneth A Ellenbogen; Patrick T Ellinor; Sabine Ernst; Guilherme Fenelon; Edward P Gerstenfeld; David E Haines; Michel Haissaguerre; Robert H Helm; Elaine Hylek; Warren M Jackman; Jose Jalife; Jonathan M Kalman; Josef Kautzner; Hans Kottkamp; Karl Heinz Kuck; Koichiro Kumagai; Richard Lee; Thorsten Lewalter; Bruce D Lindsay; Laurent Macle; Moussa Mansour; Francis E Marchlinski; Gregory F Michaud; Hiroshi Nakagawa; Andrea Natale; Stanley Nattel; Ken Okumura; Douglas Packer; Evgeny Pokushalov; Matthew R Reynolds; Prashanthan Sanders; Mauricio Scanavacca; Richard Schilling; Claudio Tondo; Hsuan-Ming Tsao; Atul Verma; David J Wilber; Teiichi Yamane
Journal:  Heart Rhythm       Date:  2017-05-12       Impact factor: 6.343

4.  Electrogram characteristics of the coronary sinus in cases requiring epicardial ablation within the coronary sinus for creating a conduction block at the left lateral mitral isthmus.

Authors:  Daisuke Sato; Hiroki Mani; Yu Makihara; Hiroki Kitajima; Yuji Nishikawa; Seno Keitaro; Yeong-Hwa Chun
Journal:  J Interv Card Electrophysiol       Date:  2018-06-27       Impact factor: 1.900

Review 5.  Arrhythmia Mechanisms Revealed by Ripple Mapping.

Authors:  George Katritsis; Vishal Luther; Prapa Kanagaratnam; Nick Wf Linton
Journal:  Arrhythm Electrophysiol Rev       Date:  2018-12

6.  Catheter ablation of atrial fibrillation in patients with severely impaired left ventricular systolic function.

Authors:  Ken Kato; Koichiro Ejima; Noritoshi Fukushima; Makoto Ishizawa; Osamu Wakisaka; Ryuta Henmi; Kentaro Yoshida; Toshiaki Nuki; Kotaro Arai; Bun Yashiro; Tetsuyuki Manaka; Kyomi Ashihara; Morio Shoda; Nobuhisa Hagiwara
Journal:  Heart Vessels       Date:  2015-01-30       Impact factor: 2.037

7.  Localized reentrant tachycardia in the aorta contiguity region mimicking perimitral atrial flutter in the context of atrial fibrillation ablation.

Authors:  Koichiro Ejima; Morio Shoda; Shinsuke Miyazaki; Bun Yashiro; Osamu Wakisaka; Tetsuyuki Manaka; Nobuhisa Hagiwara
Journal:  Heart Vessels       Date:  2012-10-19       Impact factor: 2.037

8.  Left atrial volume and dominant frequency of atrial fibrillation in patients undergoing catheter ablation of persistent atrial fibrillation.

Authors:  Kentaro Yoshida; Amir B Rabbani; Hakan Oral; David Bach; Fred Morady; Aman Chugh
Journal:  J Interv Card Electrophysiol       Date:  2011-06-14       Impact factor: 1.900

9.  2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society.

Authors:  Hugh Calkins; Karl Heinz Kuck; Riccardo Cappato; Josep Brugada; A John Camm; Shih-Ann Chen; Harry J G Crijns; Ralph J Damiano; D Wyn Davies; John DiMarco; James Edgerton; Kenneth Ellenbogen; Michael D Ezekowitz; David E Haines; Michel Haissaguerre; Gerhard Hindricks; Yoshito Iesaka; Warren Jackman; José Jalife; Pierre Jais; Jonathan Kalman; David Keane; Young-Hoon Kim; Paulus Kirchhof; George Klein; Hans Kottkamp; Koichiro Kumagai; Bruce D Lindsay; Moussa Mansour; Francis E Marchlinski; Patrick M McCarthy; J Lluis Mont; Fred Morady; Koonlawee Nademanee; Hiroshi Nakagawa; Andrea Natale; Stanley Nattel; Douglas L Packer; Carlo Pappone; Eric Prystowsky; Antonio Raviele; Vivek Reddy; Jeremy N Ruskin; Richard J Shemin; Hsuan-Ming Tsao; David Wilber
Journal:  Heart Rhythm       Date:  2012-03-01       Impact factor: 6.343

10.  Atrial tachycardias arising from ablation of atrial fibrillation: a proarrhythmic bump or an antiarrhythmic turn?

Authors:  Ashok J Shah; Amir Jadidi; Xingpeng Liu; Shinsuke Miyazaki; Andrei Forclaz; Isabelle Nault; Lena Rivard; Nick Linton; Olivier Xhaet; Nicolas Derval; Frederic Sacher; Pierre Bordachar; Philippe Ritter; Meleze Hocini; Pierre Jais; Michel Haissaguerre
Journal:  Cardiol Res Pract       Date:  2010-04-07       Impact factor: 1.866

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.